Intraocular Pressure Effects of Pegaptanib (Macugen) Injections in Patients With and Without Glaucoma

American Journal of Ophthalmology

Volumn 143, Issue 6, 2007, Pages 1034-1035

  Frenkel, Ronald E P ^a,b   Mani, Lakshmi ^a   Toler, Allison R ^a,b   Frenkel, Max P C ^a  

^a Eye Research Foundation   (United States)

^b East Florida Eye Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGAPTANIB;

ARTICLE; CONTROLLED STUDY; DRUG EFFECT; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT;

AGED; ANTIHYPERTENSIVE AGENTS; APTAMERS, NUCLEOTIDE; CHRONIC DISEASE; GLAUCOMA, OPEN-ANGLE; HUMANS; INJECTIONS; INTRAOCULAR PRESSURE; MACULAR DEGENERATION; RETROSPECTIVE STUDIES; TIME FACTORS; TONOMETRY, OCULAR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 34248576265     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2007.01.052     Document Type: Article

References (3)

1. Hariprasad S.M., Shah G.K., and Blinder K.J. Short-term intraocular pressure trends following intravitreal pegaptanib (Macugen) injection. Am J Ophthalmol 141 (2006) 200-201
2. VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group. Pegaptanib sodium for neovascularization age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 113 (2006) 992-1001
3. Bio-Rad Tono Pen2 Tonometer [instruction manual]; Bio-Rad (1997) Santa Ana, California